JP2017515508A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515508A5
JP2017515508A5 JP2017512646A JP2017512646A JP2017515508A5 JP 2017515508 A5 JP2017515508 A5 JP 2017515508A5 JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017515508 A5 JP2017515508 A5 JP 2017515508A5
Authority
JP
Japan
Prior art keywords
hepatitis
hbv
antigen
subject
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515508A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030100 external-priority patent/WO2015175380A1/en
Publication of JP2017515508A publication Critical patent/JP2017515508A/ja
Publication of JP2017515508A5 publication Critical patent/JP2017515508A5/ja
Pending legal-status Critical Current

Links

JP2017512646A 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン Pending JP2017515508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994166P 2014-05-16 2014-05-16
US61/994,166 2014-05-16
PCT/US2015/030100 WO2015175380A1 (en) 2014-05-16 2015-05-11 VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

Publications (2)

Publication Number Publication Date
JP2017515508A JP2017515508A (ja) 2017-06-15
JP2017515508A5 true JP2017515508A5 (2) 2018-06-21

Family

ID=54480490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512646A Pending JP2017515508A (ja) 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン

Country Status (8)

Country Link
US (1) US9987353B2 (2)
EP (1) EP3143144A4 (2)
JP (1) JP2017515508A (2)
CN (1) CN106459998A (2)
AU (1) AU2015259470A1 (2)
BR (1) BR112016026721A2 (2)
CA (1) CA2948181A1 (2)
WO (1) WO2015175380A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3402888T3 (pl) * 2016-01-12 2021-04-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Środki i sposoby leczenia hbv
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
US10793876B2 (en) 2016-12-29 2020-10-06 Virongy L.L.C. Retro- and lenti-HBV hybrid vectors and constructs
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
CA3099726A1 (en) 2018-05-10 2019-11-14 Clearb Therapeutics Ltd. Methods and compositions for the treatment of hepatitis b infection
EP3875470A4 (en) * 2018-10-05 2023-01-18 RNAGENE Inc. CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF
CN119770638A (zh) 2019-09-30 2025-04-08 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN115397838A (zh) 2020-01-10 2022-11-25 卡罗根公司 溶瘤病毒样囊泡的组合物和使用方法
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞（ｖｌｖ）プラットフォーム
CN115747174B (zh) * 2022-09-15 2026-02-03 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
KR20250103763A (ko) * 2022-11-07 2025-07-07 시아먼 유니버시티 융합 단백질 및 이를 포함하는 입자형 항원

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090594A2 (en) * 2008-01-11 2009-07-23 Yale University Alphavirus based vectors
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
CA2626253A1 (en) * 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2015259472A1 (en) 2014-05-16 2016-11-10 Yale University Evolution of high-titer virus-like vesicles for vaccine applications

Similar Documents

Publication Publication Date Title
JP2017515508A5 (2)
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
JP2019526580A5 (2)
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
Wang et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
JP6259831B2 (ja) Ｃ型肝炎ウイルスに対するキメラワクチン抗原
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
CN103757032B (zh) 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法
Davis DNA-based immunization against hepatitis B: experience with animal models
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
WO2005056051A2 (en) Hepatitis b vaccines and compositions
JP2025504364A (ja) 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
US20100322965A1 (en) Viral vaccine vectors
Edwards et al. Developing mucosal vaccines for SARS-cov-2: What will it take?
pertussis Novavax et al. Covid-19 Vaccines: Several technologies at work
De Ganzó et al. Virus-Like Particles: Applications in Reverse Vaccinology
RU2353651C2 (ru) Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с
HILLEMAN Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486, USA
JP2008508890A6 (ja) 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用
Camus Development and characterization of Lassa virus vaccines and mouse model